Brian I. Rini
Vanderbilt University
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
Renal cell carcinoma treatment
Strong evidence · 9 supporting papers · latest 2026
Cancer, Hypoxia, and Metabolism
Strong evidence · 3 supporting papers · latest 2026
Bladder and Urothelial Cancer Treatments
Solid evidence · 2 supporting papers · latest 2026
Ferroptosis and cancer prognosis
Solid evidence · 5 supporting papers · latest 2026
Cancer Genomics and Diagnostics
Solid evidence · 2 supporting papers · latest 2026
Single-cell and spatial transcriptomics
Solid evidence · 3 supporting papers · latest 2026
Cancer Immunotherapy and Biomarkers
Solid evidence · 3 supporting papers · latest 2026
Angiogenesis and VEGF in Cancer
Solid evidence · 1 supporting paper · latest 2026
Publications (15)
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer
2026DOIPMID 42386974
Is it time to reassess standard toxicity and patient reported outcomes methodologies for the adjuvant use of immune checkpoint inhibitors (ICIs)?
2026DOIPMID 42744249
Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank
2026DOIPMID 42731937
10 Outcomes of Patients with Renal Cell Carcinoma Achieving Pathologic Complete or Major Response After Consolidative Nephrectomy Following Immune Checkpoint Inhibitor Therapy
2026DOI
Not All Predictors Of RCC Clusters Are The Same: An individual sample predictive model to classify patients with metastatic renal cell carcinoma
2026DOI
66 Relationship Between Health-related Quality of Life and Efficacy in the Phase 3 LITESPARK-005 Study of Belzutifan versus Everolimus in Previously Treated Advanced Clear Cell Renal Cell Carcinoma
2026DOI
41 Clinical Utility of Ultrasensitive ctDNA Detection Across the Renal Cell Carcinoma Disease Spectrum: A Multi-Cohort Retrospective Study
2026DOI
3 Safety Profile of Casdatifan Monotherapy in Patients with Clear Cell Renal Cell Carcinoma: Pooled Analysis of the ARC-20 Study (NCT05536141)
2026DOI
Abstract 7898: Clinical benefit of the HIF-2α inhibitor casdatifan (Cas) across molecular subtypes in clear cell renal cell carcinoma (ccRCC) patients from the ARC-20 Clinical Study
2026DOI
69 Spatial Proteomics Profiling Identifies Prognostic Biomarkers in Papillary Renal Cell Carcinoma
2026DOI
20 PF-08634404 (SSGJ-707), a Tetravalent PD-1/VEGF Bispecific Antibody for the Treatment of Renal Cell Carcinoma (NCT07227415)
2026DOI
13 Molecular and Clinical Characterization of Early-Onset Renal Cell Carcinoma (eoRCC): A Real-World Multi-Omics Analysis
2026DOI
Podcast on the emerging role of PD-(L)1/VEGF bispecific antibodies in the evolving advanced renal cell carcinoma treatment landscape
2026DOI
Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer
2026DOIPMID 42552389
Podcast on the emerging role of PD-(L)1/VEGF bispecific antibodies in the evolving advanced renal cell carcinoma treatment landscape
2026DOI
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Vanderbilt University
Source: OpenAlex · retrieved 2026-09-29